Disease Markers / 2013 / Article / Tab 1

Research Article

Comparison of the Diagnostic Accuracy of the MSLN Gene Products, Mesothelin and Megakaryocyte Potentiating Factor, as Biomarkers for Mesothelioma in Pleural Effusions and Serum

Table 1

Comparison of antibody-based assay results for megakaryocyte potentiating factor.

Report Manufacturer of assay Antibodies used Sensitivity for MMSpecificity
cf benign and controlscf malignancyOverall

Onda et al., 2006 [12]AuthorsMPF25 and MPF4951/56 (91%)0/70100%
Shiomi et al., 2006* [13]Authors7E7 and PoAb-2827/70/130/3100%
Shiomi et al., 2008* [14]Authors7E7 and PoAb-28229/39 (74%)87% (46/356)
Shiomi et al., 2008* [14]Authors7E7 and 16K1628/39 (72%)96% (14/356)
Creaney et al., 2008 [11]IBL, Japan7E7 and PoAb-28221/66 (32%)3/702/3095%
Iwahori et al., 2008 [15]Authors20-10 and 41-2820/27 (74%)1/4714/8288%
Hollevoet et al., 2010* [16]MBL, Japan20-10 and 41-2858/85 (68%)10/3593/6397%

Values extrapolated from the presented data.
IBL: Immuno-Biologic Laboratories (Gunma, Japan).
MBL: Medical & Biological Laboratories (Nagano, Japan).

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.